Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.
.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GLP-1 Receptor Agonists | Drug | Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of sarcopenia / sarcopenic obesity | From February 2026 to december 2056 |
| Measure | Description | Time Frame |
|---|---|---|
| Myokines levels in serum or plasma | Myokines levels in serum or plasma as measured by ELISA | February 2026 to December 2056 |
| Myokine expression | Myokine expression in muscle as measured by RT-qPCR or RNA-Seq |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
People with metabolic or endocrine diseases
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Laura Orioli, MD, PhD | Contact | +32494507621 | laura.orioli@saintluc.uclouvain.be |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cliniques Universitaires Saint-Luc | Recruiting | Woluwe-Saint-Pierre - Sint-Pieters-Woluwe | 1150 | Belgium |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Mar 7, 2026 | May 9, 2026 |
Not provided
Not provided
Not provided
Not provided
Serum, plasma, muscle tissue
| February 2026 to December 2056 |
| Prevalence of MASLD | MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis | March 2026 to December 2056 |
| Prevalence of MASH | Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis | March 2026 to December 2056 |
| Prot_000.pdf |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D009765 | Obesity |
| D050177 | Overweight |
| D003480 | Cushing Syndrome |
| D008659 | Metabolic Diseases |
| D004700 | Endocrine System Diseases |
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000308 | Adrenocortical Hyperfunction |
| D000307 | Adrenal Gland Diseases |
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
Not provided
Not provided
| ID | Term |
|---|---|
| D000097789 | Glucagon-Like Peptide-1 Receptor Agonists |
| ID | Term |
|---|---|
| D007004 | Hypoglycemic Agents |
| D045505 | Physiological Effects of Drugs |
| D020228 | Pharmacologic Actions |
| D020164 | Chemical Actions and Uses |
Not provided
Not provided